Spotlight
Topic
Brand Insights
Subscribe
- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Regulation: OK After All
By Kevin Gopal
Article
Pharmaceutical Executive
Pharmaceutical ExecutivePharmaceutical Executive-04-01-2001
Volume 0
Issue 0
London-The National Institute of Clinical Excellence (NICE) has decided that Roche's Xenical (orlistat) should be available from the National Health Service for managing obesity and its related problems, but it should not be viewed as a slimming pill.
Articles in this issue
Annual Reports: Size Doesn't Matter
Internet DTC - Minding Your P's & Q's
Regulation: Two-Track Plan
Policy: Tectonic Shift
Liberated?
A Matter of Taste
Partnerships: Bargaining Biotechs
Pediatric Mandate
Genentech's Passion for Patients
Regulation: OK After All
Beyond Training
Balancing Haves & Have-Nots
The Changing OTC Landscape
Recent Videos
Related Content
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Podcast
Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
